| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2771769 | Seminars in Arthritis and Rheumatism | 2011 | 13 Pages |
Abstract
Naproxcinod 750 mg bid and 375 mg bid demonstrated superior efficacy over placebo for treatment of OA and were well tolerated over 1 year. Naproxcinod 750 mg bid was noninferior to naproxen 500 mg bid.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Thomas J. MD, PhD, Marc C. MD, MPH, Christopher E. MD, Brigitte MD, Hayet MSc, Maarten MD, PhD,